Britain’s Most Admired... Health and household

In a bad year for pharma, GlaxoSmithKline is still on top but paying for poor sales of controversial diabetes treatment Avandia.

1. GlaxoSmithKline – 64.3
2. AstraZeneca – 60.6
3. Reckitt Benckiser – 59.1
4. Smith & Nephew – 58.5
5. Shire – 54.8

Third-quarter profits are down 4% to £1.88bn, with £700m annual cost cuts announced. CEO-in-waiting Andrew Witty has his work cut out. Second-placed AstraZeneca is similarly beleaguered, announcing a 7% fall in third-quarter profits, with patent battles looming over its top-selling products. Acquisitions costs related to the £15bn purchase of American biotechnology firm Medimmune have hit hard. Bronze medalists: at Reckitt Benckiser, year-to-date net revenue grew by 11% in the third quarter, and full year targets have been raised. Growth was driven by new products and a boom – thank you, British weather – in Nurofen and Strepsils.

Sign in to continue

Sign in

Trouble signing in?

Reset password: Click here


Call: 020 8267 8121



  • Up to 4 free articles a month
  • Free email bulletins

Register Now

Get 30 days free access

Sign up for a 30 day free trial and get:

  • Full access to
  • Exclusive event discounts
  • Management Today's print magazine

Join today